<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>SCOPOLAMINE HYDROBROMIDE- scopolamine hydrobromide injection, solution </strong><br>APP Pharmaceuticals, LLC<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>Scopolamine Hydrobromide Injection USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="d664812f-6ba6-40e5-a926-06cac48e53f6"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">FOR INTRAMUSCULAR, INTRAVENOUS OR SUBCUTANEOUS USE</p>
<p><span class="Italics"><span class="Emphasis">Protect From Light</span></span></p>
<p><span class="Italics"><span class="Emphasis">Opaque covering needed until contents used</span></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ad145232-0e06-43e6-b85a-1eb488d55eb6"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Scopolamine Hydrobromide Injection, USP is a sterile solution of scopolamine hydrobromide (C<span class="Sub">17</span>H<span class="Sub">21</span>NO<span class="Sub">4</span> • HBr • 3H<span class="Sub">2</span>O) in Water for Injection.  The injection is preserved with methylparaben 0.18% and propylparaben 0.02%.  Scopolamine Hydrobromide Injection is intended for intramuscular, intravenous and subcutaneous use.  The pH (3.5-6.5) is adjusted with hydrobromic acid if necessary.</p>
<p>The structural formula is:</p>
<p><img alt="scopolamine-structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85b3ca0-89ce-44fe-b748-62e160e8c349&amp;name=scopolamine-hydrobromide-injection-usp-figure-1-scopolamine-structure.jpg"> </p>
<p> </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="e3425135-a285-441e-a184-d1826d59409c"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Scopolamine hydrobromide is one of the major antimuscarinic agents that inhibit the action of acetylcholine (ACh) on autonomic effectors innervated by postganglionic cholinergic nerves as well as on smooth muscles that lack cholinergic innervation.  It exerts little effects on the actions of ACh at nicotinic receptor sites such as autonomic ganglia.  The major action of this antimuscarinic agent is a surmountable antagonism to ACh and other muscarinic agents.</p>
<p>As compared with atropine, scopolamine differs only quantitatively in antimuscarinic actions.  Scopolamine has a stronger action on the iris, ciliary body and certain secretory glands such as salivary, bronchial and sweat.  Scopolamine, in therapeutic doses, normally causes <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and dreamless sleep with a reduction in rapid-eye-movement sleep.  However, the same doses occasionally cause <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> or <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, especially in the presence of severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.  Scopolamine depresses the EEG arousal response to photostimulation.  It is more potent than atropine on the antitremor activity (<span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>) in animals induced by surgical lesions.  Scopolamine is effective in preventing <span class="product-label-link" type="condition" conceptid="30284" conceptname="Motion sickness">motion sickness</span> by acting on the maculae of the utricle and saccule.</p>
<p>Scopolamine, although less potent than atropine, has been used frequently in preanesthetic medication for the purpose of inhibiting the secretions of the nose, mouth, pharynx and bronchi and reduces the occurrence of <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> during general anesthesia.  Scopolamine is less potent in the decrease of cardiac rate, but not in the changes of blood pressure or <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>.  Like other antimuscarinic agents, scopolamine has been used widely in the treatment of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span> and as an antispasmodic agent for G.I. disorders.  This is due to the fact that scopolamine reduces salivary secretion, the gastric secretion (both the volume and acid content), and also it inhibits the motor activity of the stomach, duodenum, jejunum, ileum and colon, characterized by a decrease in tone, amplitude and frequency of peristaltic contractions.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ce4e8d7b-34c2-4a86-8c48-e2d5b8fe991d"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Scopolamine Hydrobromide Injection, USP is indicated as a sedative and tranquilizing depressant to the central nervous system.  In its peripheral actions, scopolamine differs from atropine in that it is a stronger blocking agent for the iris, ciliary body and salivary, bronchial and sweat glands but is weaker in its action on the heart (in which it is incapable of exerting actions in tolerated doses), the intestinal tract and bronchial musculature.</p>
<p>In addition to the usual uses for antimuscarinic drugs, scopolamine is employed for its central depressant actions as a sedative.  Frequently it is given as a preanesthetic medicament for both its sedative-tranquilizing and antisecretory actions.  It is an effective antiemetic.  It is used in maniacal states, in <span class="product-label-link" type="condition" conceptid="377830" conceptname="Alcohol withdrawal delirium">delirium tremens</span> and in obstetrics.  As a mydriatic and cycloplegic, it has a somewhat shorter duration (3 to 7 days) and intraocular pressure is affected less markedly than with atropine.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="e19b640a-25de-4ae6-a50b-33ed9c98cb86"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Scopolamine hydrobromide is contraindicated in patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, since administration of the drug could raise the intraocular pressure to dangerous levels.  However, this will not happen for side-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> patients.  Repeated administration of scopolamine to a patient with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> is considered to be potentially hazardous.  Patients hypersensitive to belladonna or to barbiturates may be hypersensitive to scopolamine hydrobromide.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="b75b4209-e84b-4364-9748-d4653defcc4a"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Addiction does not occur, although <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> have been reported in patients with <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> upon sudden withdrawal of large doses of scopolamine.  Scopolamine is one of the most important drugs of the belladonna group from the standpoint of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>; infants and young children are especially susceptible to the belladonna alkaloids.  Scopolamine is usually stated more toxic than atropine.  Idiosyncrasy is more common with scopolamine than with atropine and ordinary therapeutic doses sometimes cause alarming reactions.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d5f65222-d6cb-44bb-92bc-f7b1ec965e77"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="d0daec6a-0914-4544-bcca-69e310723552"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">If there is <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, dark glasses should be worn.  Appropriate dosage precautions must be taken with infants, children, persons with mongolism, <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span>, <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span>, or light irides.  Elevated intraocular pressure, urinary difficulty and retention and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> are more probable in elderly persons.  Men with <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> should especially be monitored for urinary function.  Because of the tachycardic effects of the drugs, care must be exercised when <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, other <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span>, coronary heart disease, congestive heart disease or <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> preexist.  Persons with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may experience both exaggerated <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.  Similarly, <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span> requires caution.  Persons with a history of allergies or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> will show a higher than normal incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b4368270-ff73-4639-9f29-fc45521ee2fa"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests<br>
</h2>
<p class="First">Barbiturates may increase Bromosulfonphthalein (BSP) levels; administration is not recommended during the 24 hours preceding the test.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b0689ffb-45d4-4239-8415-fe97e7b41d56"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">Other drugs, such as phenothiazines, tricyclic antidepressants, certain antihistamines, meperidine, etc., which have weak antimuscarinic activity, may considerably intensify the effects of antimuscarinic drugs.  Aluminum- and magnesium trisilicate-containing antacids have been shown to decrease the absorption of some antimuscarinic drugs and may possibly do so with all of them.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fcba7fd0-8186-4d73-a6af-241dbb3d0318"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy Category C<br>
</h2>
<p class="First">Scopolamine hydrobromide can pass the placental barrier; the threat to the fetus <span class="Italics"><span class="Emphasis">in utero</span></span> is unknown, but use during pregnancy may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate and may contribute to neonatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> due to reduction in Vitamin K-dependent clotting factors in the neonate.</p>
<p>Scopolamine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fd5dbcf5-31d5-4907-a96e-54abba287db7"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers<br>
</h2>
<p class="First">Problems in humans have not been documented; however, risk-benefit must be considered since barbiturates and belladonna alkaloids are excreted in breast milk.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d0ef2f88-e1a0-4bd8-a22d-20c4361f8798"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">With nearly all antimuscarinic drugs, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> is the first and <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> is the second most common side effect.  <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span> and difficulty in swallowing occur when the mouth and esophagus become sufficiently dry; chronic <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> also fosters <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">dental caries</span>.  Suppression of <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> causes reflexive <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and heat intolerance and can result in <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat exhaustion</span> or <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> in a hot environment; it also contributes to the <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> seen in <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.  <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span> frequently occurs, especially with scopolamine; <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span> are consequences of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>.  <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">Cycloplegia</span> (which exacerbates <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>) occurs approximately concomitantly with <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, but usually higher doses are required.  In susceptible persons, especially the elderly, <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span> may contribute to an elevation of intraocular pressure.  Difficulty in urination and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> may occur.  <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> is a common side effect.  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, even bowel stasis, may occur.</p>
<p>In the larger therapeutic doses, scopolamine may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and locomotor difficulties.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="de9e329e-964b-4cd0-bdae-b0ef62d9bd6e"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Serious systemic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> can occur even from topical ophthalmologic application, especially in children, since both local absorption and nasolacrimal drainage into the gut can deliver considerable amounts to the circulation.  In serious <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, nonallergenic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, circulatory or respiratory collapse, even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in addition to all aforenamed effects, may occur.  Children, especially infants and children with mongolism, <span class="product-label-link" type="condition" conceptid="4300746" conceptname="Spastic paralysis">spastic paralysis</span> or <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span>, are more sensitive than adults to the toxic effects.</p>
<p>If marked <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> is present and more specific treatment is not available, diazepam is most suitable for sedation and for control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.  Large doses should be avoided because the central depressant action may coincide with the <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> occurring late in belladonna <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.  Phenothiazines should not be used because their antimuscuranic action is likely to intensify toxicity and may plunge the patient into <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.  Artificial respiration with oxygen may be necessary.  Ice bags and alcohol sponges help to reduce <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, especially in children.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="a13ae81e-c9c5-4186-ae0f-2e32748bba96"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="f7c94f85-d301-4672-8a78-760374fbcf19"></a><a name="section-10.1"></a><p></p>
<h2>Adult</h2>
<p class="First">For obstetric <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span> or preoperative sedation, 0.32 to 0.65 mg (320 to 650 mcg).</p>
<p>For sedation or tranquilization, 0.6 mg (600 mcg) 3 or 4 times a day.</p>
<p>Subcutaneous, as an antiemetic, 0.6 to 1 mg.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b066b157-1c4f-439d-8ec6-b02ded57cfe7"></a><a name="section-10.2"></a><p></p>
<h2>Pediatric</h2>
<p class="First">Age 6 mo. to 3 yr., 0.1 to 0.15 mg (100 to 150 mcg).  Age 3 to 6 yr., 0.2 to 0.3 mg (200 to 300 mcg).</p>
<p>Subcutaneous, as antiemetic, 0.006 mg (6 mcg) per kg.</p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">              Dosage Equivalents</span></span></p>
<table><tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><p class="First">1 mg (1000 mcg)/mL</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1     mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">      (1000 mcg)         </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1    mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.8  mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(800 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.8  mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.6  mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(600 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.6  mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.5  mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(500 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.5  mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.4  mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(400 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.4  mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.3  mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(300 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.3  mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.2  mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(200 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.2  mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.1  mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(100 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.1  mL</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><p class="First">0.4 mg (400 mcg)/mL</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.4  mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(400 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1    mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.3  mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(300 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">   0.75 mL   </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">   0.25 mg   </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(250 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.63 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.2  mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(200 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.50 mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.15 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(150 mcg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.38 mL</p></td>
</tr>
</tbody></table>
<p>Belladonna alkaloids provide a therapeutic effect in about 1 or 2 hours with a duration of about 4 hours.</p>
<p>Geriatric and debilitated patients may respond to the usual doses with <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>; lower doses may be required in such patients.</p>
<p>Close supervision is recommended for infants, blondes, mongoloids and children with <span class="product-label-link" type="condition" conceptid="4300746" conceptname="Spastic paralysis">spastic paralysis</span> or <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span>, since an increased responsiveness to belladonna alkaloids has been reported in these patients and dosage adjustments are often required.</p>
<p>Administration of belladonna alkaloids and barbiturates 30 to 60 minutes before meals is recommended to maximize absorption and, when issued for reducing stomach acid formation, to allow its effect to coincide better with antacid administration following the meal.</p>
<p>Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ee101680-6bfc-481a-8b4e-1294f510a54c"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Scopolamine Hydrobromide Injection, USP is supplied as: </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Strength</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">26801</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-268-01      </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">0.4 mg/mL       </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 mL in a 2 mL multiple dose vial, in packages of 25.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">27001</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-270-01</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 mg/mL</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 mL in a 2 mL multiple dose vial, in packages of 25.</p></td>
</tr>
</tbody></table>
<p><span class="Bold"><span class="Emphasis">PROTECT FROM LIGHT.</span></span></p>
<p>
Use only if solution is clear and seal intact.</p>
<p>
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="aa43b1da-0a8c-4d3d-a8ce-e71b0300ee1f"></a><a name="section-12"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85b3ca0-89ce-44fe-b748-62e160e8c349&amp;name=scopolamine-hydrobromide-injection-usp-figure-2-add_band_logo.jpg"></div>
<p class="First">45818C</p>
<p>Revised: April 2008</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d8567b2c-eb5d-42c5-8aa7-947a23395959"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Scopolamine 1 mL Multiple Dose Vial Label</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-268-01</p>
<p>26801</p>
<p><span class="Bold"><span class="Emphasis">Scopolamine Hydrobromide Injection, USP</span></span></p>
<p><span class="Bold"><span class="Emphasis">0.4 mg/mL</span></span></p>
<p>For IM, IV or SC Use</p>
<p><span class="Bold"><span class="Emphasis">1 mL</span></span> Multiple Dose Vial</p>
<p>Usual Dosage: See insert.</p>
<p>Protect From Light.</p>
<p> </p>
<p><img alt="26801-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85b3ca0-89ce-44fe-b748-62e160e8c349&amp;name=scopolamine-hydrobromide-injection-usp-figure-3-26801-vial.jpg"> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Scopolamine 1 mL Multiple Dose Vial Tray Label</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-268-01</p>
<p>26801</p>
<p><span class="Bold"><span class="Emphasis">Scopolamine Hydrobromide Injection, USP</span></span></p>
<p><span class="Bold"><span class="Emphasis">0.4 mg/mL</span></span></p>
<p>For IM, IV or SC Use</p>
<p><span class="Bold"><span class="Emphasis">1 mL</span></span> Multiple Dose Vial</p>
<p>Rx only</p>
<br><p> </p>
<p><img alt="26801-tray" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b85b3ca0-89ce-44fe-b748-62e160e8c349&amp;name=scopolamine-hydrobromide-injection-usp-figure-4-26801-tray.jpg"> </p>
<p> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SCOPOLAMINE HYDROBROMIDE 		
					</strong><br><span class="contentTableReg">scopolamine hydrobromide injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-268</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SCOPOLAMINE HYDROBROMIDE</strong> (SCOPOLAMINE) </td>
<td class="formItem">SCOPOLAMINE HYDROBROMIDE</td>
<td class="formItem">0.4 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROBROMIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-268-01</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">10/18/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>APP Pharmaceuticals, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">APP Pharmaceuticals, LLC</td>
<td class="formItem"></td>
<td class="formItem">840771732</td>
<td class="formItem">MANUFACTURE(63323-268)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>55057dd7-f616-4919-afab-21a0a5eef69e</div>
<div>Set id: b85b3ca0-89ce-44fe-b748-62e160e8c349</div>
<div>Version: 1</div>
<div>Effective Time: 20120830</div>
</div>
</div> <div class="DistributorName">APP Pharmaceuticals, LLC</div></p>
</body></html>
